Journal Article
. 2003 Mar;21(6).
doi: 10.1200/JCO.2003.02.063.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer

I Craig Henderson 1 Donald A Berry  George D Demetri  Constance T Cirrincione  Lori J Goldstein  Silvana Martino  James N Ingle  M Robert Cooper  Daniel F Hayes  Katherine H Tkaczuk  Gini Fleming  James F Holland  David B Duggan  John T Carpenter  Emil Frei  Richard L Schilsky  William C Wood  Hyman B Muss  Larry Norton  
Affiliations
  • PMID: 12637460
  •     286 citations

Abstract

Purpose: This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival.

Patients And Methods: After surgical treatment, 3,121 women with operable breast cancer and involved lymph nodes were randomly assigned to receive a combination of cyclophosphamide (C), 600 mg/m(2), with one of three doses of doxorubicin (A), 60, 75, or 90 mg/m(2), for four cycles followed by either no further therapy or four cycles of paclitaxel at 175 mg/m(2). Tamoxifen was given to 94% of patients with hormone receptor-positive tumors.

Results: There was no evidence of a doxorubicin dose effect. At 5 years, disease-free survival was 69%, 66%, and 67% for patients randomly assigned to 60, 75, and 90 mg/m(2), respectively. The hazard reductions from adding paclitaxel to CA were 17% for recurrence (adjusted Wald chi(2) P =.0023; unadjusted Wilcoxon P =.0011) and 18% for death (adjusted P =.0064; unadjusted P =.0098). At 5 years, the disease-free survival (+/- SE) was 65% (+/- 1) and 70% (+/- 1), and overall survival was 77% (+/- 1) and 80% (+/- 1) after CA alone or CA plus paclitaxel, respectively. The effects of adding paclitaxel were not significantly different in subsets defined by the protocol, but in an unplanned subset analysis, the hazard ratio of CA plus paclitaxel versus CA alone was 0.72 (95% confidence interval, 0.59 to 0.86) for those with estrogen receptor-negative tumors and only 0.91 (95% confidence interval, 0.78 to 1.07) for patients with estrogen receptor-positive tumors, almost all of whom received adjuvant tamoxifen. The additional toxicity from adding four cycles of paclitaxel was generally modest.

Conclusion: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.

American Society for Clinical Oncology 39th Annual Meeting, Chicago, Illinois, USA, 31 May to 3 June 2003: breast cancer neoadjuvant and adjuvant chemotherapy--prognostic and predictive markers.
Helena Earl, American Society for Clinical Oncology.
Breast Cancer Res, 2003 Oct 29; 5(6). PMID: 14580243    Free PMC article.
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer.
Tamara Shenkier, Lorna Weir, +4 authors, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ, 2004 Mar 17; 170(6). PMID: 15023926    Free PMC article.
Systematic Review.
The curability of breast cancer and the treatment of advanced disease.
Valentina Guarneri, Pier Franco Conte.
Eur J Nucl Med Mol Imaging, 2004 Apr 27; 31 Suppl 1. PMID: 15107948
Review.
Treatment of locally advanced breast cancer.
Deepu Mirchandani, Kamal Haider, Haji Chalchal.
CMAJ, 2004 Aug 04; 171(3). PMID: 15289403    Free PMC article.
Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer.
Dene Simpson, Greg L Plosker.
Drugs, 2004 Aug 11; 64(16). PMID: 15301565
Review.
Adjuvant chemotherapy for primary breast cancer.
Monica Fornier, Clifford Hudis.
Curr Oncol Rep, 2004 Dec 22; 7(1). PMID: 15610682
Review.
The influence of aging on the early detection, diagnosis, and treatment of breast cancer.
Marisa F Siebel, Hyman B Muss.
Curr Oncol Rep, 2004 Dec 22; 7(1). PMID: 15610683
Review.
Sensitive, noninvasive detection of lymph node metastases.
Mukesh G Harisinghani, Ralph Weissleder.
PLoS Med, 2005 Jan 05; 1(3). PMID: 15630471    Free PMC article.
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
A Urruticoechea, C D Archer, +6 authors, S R D Johnston.
Br J Cancer, 2005 Feb 03; 92(3). PMID: 15685237    Free PMC article.
Dose-dense adjuvant chemotherapy for primary breast cancer.
Monica Fornier, Larry Norton.
Breast Cancer Res, 2005 Mar 04; 7(2). PMID: 15743513    Free PMC article.
Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
Ta-Chung Chao, Zyting Chu, +8 authors, Po-Min Chen.
Invest New Drugs, 2005 Mar 04; 23(2). PMID: 15744594
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.
K H Yeh, Y S Lu, +7 authors, A L Cheng.
Br J Cancer, 2005 Mar 17; 92(6). PMID: 15770209    Free PMC article.
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Roman Rouzier, Radhika Rajan, +13 authors, Lajos Pusztai.
Proc Natl Acad Sci U S A, 2005 May 26; 102(23). PMID: 15914550    Free PMC article.
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
Yudi Pawitan, Judith Bjöhle, +17 authors, Jonas Bergh.
Breast Cancer Res, 2005 Nov 11; 7(6). PMID: 16280042    Free PMC article.
Highly Cited.
Medical treatment of early breast cancer. III: chemotherapy.
Ian Smith, Susan Chua.
BMJ, 2006 Jan 21; 332(7534). PMID: 16424494    Free PMC article.
Review.
Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.
W Jonat, K I Pritchard, R Sainsbury, J G Klijn.
J Cancer Res Clin Oncol, 2006 Jan 26; 132(5). PMID: 16435142
Review.
FADD phosphorylation is critical for cell cycle regulation in breast cancer cells.
S Matsuyoshi, K Shimada, +2 authors, N Konishi.
Br J Cancer, 2006 Feb 02; 94(4). PMID: 16450001    Free PMC article.
Impact of a scientific presentation on community treatment patterns for primary breast cancer.
Sharon H Giordano, Zhigang Duan, +3 authors, James S Goodwin.
J Natl Cancer Inst, 2006 Mar 16; 98(6). PMID: 16537830    Free PMC article.
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
S Kümmel, J Krocker, +5 authors, D Elling.
Br J Cancer, 2006 Apr 20; 94(9). PMID: 16622463    Free PMC article.
Early breast cancer.
Tomoyoshi Suzuki, Masakazu Toi, +7 authors, Noriko Kamata.
Int J Clin Oncol, 2006 Apr 20; 11(2). PMID: 16622745
Review.
Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment.
K Mimori, N Sadanaga, +7 authors, M Mori.
Br J Cancer, 2006 May 25; 94(12). PMID: 16721363    Free PMC article.
A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer.
Michiya Kobayashi, Akira Tsuburaya, +3 authors, Junichi Sakamoto.
Gastric Cancer, 2006 Jun 13; 9(2). PMID: 16767367
Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy.
Fabrice Andre, Lajos Pusztai.
Pharm Res, 2006 Aug 15; 23(9). PMID: 16906452
Review.
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
Elizabeth B Lamont, James E Herndon, +5 authors, Cancer and Leukemia Group B.
J Natl Cancer Inst, 2006 Sep 21; 98(18). PMID: 16985253    Free PMC article.
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
Lyndsay N Harris, Gloria Broadwater, +10 authors, Lynn Dressler.
Breast Cancer Res, 2006 Nov 30; 8(6). PMID: 17129383    Free PMC article.
Taxanes in breast cancer: an update.
Alison K Conlin, Andrew D Seidman.
Curr Oncol Rep, 2006 Dec 14; 9(1). PMID: 17164044
Review.
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain.
R Colomer, A Llombart-Cussac, +7 authors, H Cortés-Funes.
Clin Transl Oncol, 2006 Dec 16; 8(12). PMID: 17169763
Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.
M Schmidt, E Bremer, +13 authors, J G Hengstler.
Br J Cancer, 2007 Jan 11; 96(2). PMID: 17211474    Free PMC article.
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Stefan Buchholz, Andrew V Schally, +5 authors, Gabor Halmos.
Proc Natl Acad Sci U S A, 2007 Jan 31; 104(6). PMID: 17261802    Free PMC article.
Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Yuri Takahashi, Yasuo Miyoshi, +3 authors, Shinzaburo Noguchi.
J Cancer Res Clin Oncol, 2007 Feb 14; 133(8). PMID: 17297610
Managing high-risk breast cancer.
Frances M Palmieri, Edith A Perez.
Semin Oncol Nurs, 2007 Feb 17; 23(1). PMID: 17303514    Free PMC article.
Review.
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer.
George Fountzilas, Dimitrios Pectasides, +7 authors, Dimosthenis Skarlos.
Med Oncol, 2007 Feb 17; 23(4). PMID: 17303906
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Kyung-Hun Lee, Seock-Ah Im, +10 authors, Yung-Jue Bang.
BMC Cancer, 2007 Apr 14; 7. PMID: 17430582    Free PMC article.
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
P Kerbrat, H Roché, +16 authors, French adjuvant Study Group.
Br J Cancer, 2007 May 17; 96(11). PMID: 17505516    Free PMC article.
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Amy Lin, Hope S Rugo.
Curr Treat Options Oncol, 2007 Jul 31; 8(1). PMID: 17660958
Review.
UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction.
Fumihiro Tanaka.
Surg Today, 2007 Oct 24; 37(11). PMID: 17952521
Review.
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.
M Debled, N Houédé, +4 authors, Louis Mauriac.
Br J Cancer, 2007 Nov 15; 97(12). PMID: 18000502    Free PMC article.
Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer.
A Goldrick, I A Olivotto, +4 authors, P T Truong.
Curr Oncol, 2007 Dec 15; 14(6). PMID: 18080014    Free PMC article.
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Minetta C Liu, George D Demetri, +16 authors, Cancer and Leukemia Group B.
Cancer Treat Rev, 2008 Feb 01; 34(3). PMID: 18234424    Free PMC article.
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
Edith A Perez, Vera J Suman, +12 authors, Richard J Rodeheffer.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250349    Free PMC article.
Highly Cited.
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
G G Kimmick, C Cirrincione, +9 authors, Cancer and Leukemia Group B.
Breast Cancer Res Treat, 2008 Feb 29; 113(3). PMID: 18306034    Free PMC article.
Update of evidence in chemotherapy for breast cancer.
Hiroyasu Yamashiro, Masakazu Toi.
Int J Clin Oncol, 2008 Mar 01; 13(1). PMID: 18307012
Review.
Avoiding the use of anthracyclines in the adjuvant therapy of breast cancer: the "TC" (docetaxel and cyclophosphamide) regimen.
Kevin R Fox.
Curr Oncol Rep, 2008 Mar 28; 10(1). PMID: 18366954
Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Elizabeth B Lamont, James E Herndon, +5 authors, Cancer and Leukemia Group B.
Med Care, 2008 Apr 05; 46(3). PMID: 18388845    Free PMC article.
Weekly paclitaxel in the adjuvant treatment of breast cancer.
Joseph A Sparano, Molin Wang, +7 authors, Nancy E Davidson.
N Engl J Med, 2008 Apr 19; 358(16). PMID: 18420499    Free PMC article.
Highly Cited.
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.
G Somlo, P Chu, +5 authors, P Danenberg.
Ann Oncol, 2008 Jul 22; 19(11). PMID: 18641005    Free PMC article.
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
A M Wardley, L Hiller, +8 authors, tAnGo Trial Collaborators.
Br J Cancer, 2008 Jul 31; 99(4). PMID: 18665163    Free PMC article.
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Lori J Goldstein, Anne O'Neill, +4 authors, Nancy E Davidson.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678836    Free PMC article.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer.
Shubham Pant, Meena P Chilukuri, Bhuvaneswari Ramaswamy.
Ther Clin Risk Manag, 2008 Aug 30; 4(2). PMID: 18728853    Free PMC article.
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.
Juan de la Haba-Rodríguez, Emilio Alba, +8 authors, Enrique Aranda.
Clin Transl Oncol, 2008 Sep 18; 10(9). PMID: 18796372
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
Mark R Green, Stephen L George, Richard L Schilsky, Cancer and Leukemia Group B.
Semin Oncol, 2008 Oct 22; 35(5). PMID: 18929146    Free PMC article.
Review.
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
A K Koutras, K T Kalogeras, +16 authors, Hellenic Cooperative Oncology Group (HeCOG).
Br J Cancer, 2008 Nov 06; 99(11). PMID: 18985033    Free PMC article.
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
Lorenzo Gianni, Shari Gelber, +9 authors, Aron Goldhirsch.
Eur J Cancer, 2008 Dec 09; 45(4). PMID: 19062268    Free PMC article.
Current indications for post-mastectomy radiation.
Maria Vilarino-Varela, Yaw Sinn Chin, Andreas Makris.
Int Semin Surg Oncol, 2009 Feb 11; 6. PMID: 19203387    Free PMC article.
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
Natasa Snoj, Philippe L Bedard, +2 authors, Martine Piccart.
Breast Cancer Res, 2009 Feb 17; 11(1). PMID: 19216727    Free PMC article.
Review.
Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005.
Edward L Korn, Boris Freidlin, Margaret Mooney.
J Clin Oncol, 2009 Feb 25; 27(10). PMID: 19237631    Free PMC article.
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Satoshi Nakayama, Yasuhiro Torikoshi, +11 authors, Naoto T Ueno.
Breast Cancer Res, 2009 Feb 26; 11(1). PMID: 19239702    Free PMC article.
Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.
Yu Shen, Wenli Dong, +3 authors, Sharon H Giordano.
Cancer, 2009 Mar 17; 115(10). PMID: 19288569    Free PMC article.
Significant impairment in immune recovery after cancer treatment.
Duck-Hee Kang, Michael T Weaver, +3 authors, John Carpenter.
Nurs Res, 2009 Mar 18; 58(2). PMID: 19289931    Free PMC article.
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
Helen K Chew, James H Doroshow, +15 authors, Kathy S Albain.
J Clin Oncol, 2009 Mar 25; 27(13). PMID: 19307510    Free PMC article.
Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.
Rebecca A Miksad, Mithat Gönen, Thomas J Lynch, Thomas G Roberts.
J Clin Oncol, 2009 Mar 25; 27(13). PMID: 19307513    Free PMC article.
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.
Sara López-Tarruella, Miguel Martín.
Breast Cancer Res, 2009 Apr 07; 11(2). PMID: 19344489    Free PMC article.
Review.
Adjuvant chemotherapy for early breast cancer in the elderly.
Mary Leung, Iulianna Shapira, Thomas Bradley, Daniel R Budman.
Curr Treat Options Oncol, 2009 Apr 11; 10(3-4). PMID: 19360475
Review.
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Robert Wesolowski, David Peereboom, +2 authors, George Thomas Budd.
Invest New Drugs, 2009 May 13; 28(4). PMID: 19434371
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Paul Ellis, Peter Barrett-Lee, +22 authors, TACT Trialists.
Lancet, 2009 May 19; 373(9676). PMID: 19447249    Free PMC article.
Breast cancer (non-metastatic).
Justin Stebbing, Geoff Delaney, Alistair Thompson.
BMJ Clin Evid, 2007 Jan 01; 2007. PMID: 19450345    Free PMC article.
Systematic Review.
Breast cancer before age 40 years.
Carey K Anders, Rebecca Johnson, +2 authors, Archie Bleyer.
Semin Oncol, 2009 May 23; 36(3). PMID: 19460581    Free PMC article.
Highly Cited. Review.
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.
Evelina Miele, Gian Paolo Spinelli, +2 authors, Silverio Tomao.
Int J Nanomedicine, 2009 Jun 12; 4. PMID: 19516888    Free PMC article.
Highly Cited. Review.
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
J Thomas De Ligio, Aneliya Velkova, Diego A R Zorio, Alvaro N A Monteiro.
Anticancer Agents Med Chem, 2009 Jun 13; 9(5). PMID: 19519295    Free PMC article.
Review.
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
Raymond Tubbs, William E Barlow, +11 authors, Daniel F Hayes.
J Clin Oncol, 2009 Jul 22; 27(24). PMID: 19620488    Free PMC article.
Chemotherapy for early-stage breast cancer: a brief history.
M Verrill.
Br J Cancer, 2009 Sep 17; 101 Suppl 1. PMID: 19756003    Free PMC article.
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Margot Burnell, Mark N Levine, +11 authors, Lois E Shepherd.
J Clin Oncol, 2009 Nov 11; 28(1). PMID: 19901117    Free PMC article.
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
Patrick G Morris, Maura Dickler, +14 authors, Chau T Dang.
J Clin Oncol, 2009 Nov 11; 27(36). PMID: 19901120    Free PMC article.
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Philippe L Bedard, Angelo Di Leo, Martine J Piccart-Gebhart.
Nat Rev Clin Oncol, 2009 Dec 10; 7(1). PMID: 19997076
Review.
Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells.
Kathryn E Reinicke, Mary J Kuffel, Matthew P Goetz, Matthew M Ames.
Cancer Chemother Pharmacol, 2009 Dec 17; 66(3). PMID: 20012292    Free PMC article.
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
Joshua A Bauer, A Bapsi Chakravarthy, +16 authors, Jennifer A Pietenpol.
Clin Cancer Res, 2010 Jan 14; 16(2). PMID: 20068102    Free PMC article.
Breast Cancer OncoGuia.
Paula Manchon, Josep M Borràs, +2 authors, Breast Cancer OncoGuia Group.
Clin Transl Oncol, 2010 Feb 17; 12(2). PMID: 20156781
Triple-negative breast cancer: role of specific chemotherapy agents.
Steven J Isakoff.
Cancer J, 2010 Feb 19; 16(1). PMID: 20164691    Free PMC article.
Review.
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
Christophe Le Tourneau, Véronique Diéras, +2 authors, Xavier Paoletti.
Target Oncol, 2010 Apr 03; 5(1). PMID: 20361265
Review.
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Chau Dang, Nancy Lin, +10 authors, Clifford Hudis.
J Clin Oncol, 2010 May 19; 28(18). PMID: 20479410    Free PMC article.
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
Sandra M Swain, Jong-Hyeon Jeong, +14 authors, Norman Wolmark.
N Engl J Med, 2010 Jun 04; 362(22). PMID: 20519679    Free PMC article.
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.
Tiffany A Traina, Ute Dugan, +4 authors, Larry Norton.
Breast Dis, 2010 Jun 04; 31(1). PMID: 20519801    Free PMC article.
Recovery of menstruation after long-term chemotherapy and endocrine therapy in pre-menopausal patients with breast cancer.
Kenichi Sakurai, Katsuhisa Enomoto, Sadao Amano.
J Cancer Res Clin Oncol, 2010 Jun 10; 137(4). PMID: 20532911
Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.
S Saibil, B Fitzgerald, +5 authors, M Clemons.
Curr Oncol, 2010 Aug 11; 17(4). PMID: 20697513    Free PMC article.
Rechallenging with anthracyclines and taxanes in metastatic breast cancer.
Carlo Palmieri, Jonathan Krell, +4 authors, David Miles.
Nat Rev Clin Oncol, 2010 Sep 03; 7(10). PMID: 20808300
Review.
New Therapeutic Options for Breast Cancer during Pregnancy.
Sibylle Loibl.
Breast Care (Basel), 2008 Jan 01; 3(3). PMID: 20824035    Free PMC article.
Is Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?
Brigitte Mlineritsch.
Breast Care (Basel), 2009 Jan 01; 4(3). PMID: 20847875    Free PMC article.
A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.
Fady B Geara, Ali Shamseddine, +3 authors, Muhieddine Seoud.
Radiat Oncol, 2010 Sep 25; 5. PMID: 20863389    Free PMC article.
Duration of chemotherapy for early stage breast cancer: have we reached the limit? What is the survival impact of amenorrhea?
Rebecca L Hirsh, Kevin R Fox.
Curr Treat Options Oncol, 2010 Nov 10; 11(3-4). PMID: 21061193
Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.
Tatiana Spicakova, Maureen M O'Brien, +2 authors, Branimir I Sikic.
Mol Cancer Ther, 2010 Nov 11; 9(11). PMID: 21062914    Free PMC article.
Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.
Marc L Citron.
Breast Care (Basel), 2008 Jan 01; 3(4). PMID: 21076605    Free PMC article.
Triple-negative breast cancer: epidemiology and management options.
Shaheenah Dawood.
Drugs, 2010 Nov 18; 70(17). PMID: 21080741
Review.
Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint.
Melanie M Badtke, Purevsuren Jambal, +4 authors, Britta M Jacobsen.
Breast Cancer Res Treat, 2011 Feb 23; 131(1). PMID: 21340479    Free PMC article.
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.
Heather L McArthur, Hope Rugo, +30 authors, Maura N Dickler.
Clin Cancer Res, 2011 Feb 26; 17(10). PMID: 21350003    Free PMC article.
Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.
Elizabeth A Mittendorf, Jacqueline S Jeruss, +9 authors, Kelly K Hunt.
J Clin Oncol, 2011 Apr 13; 29(15). PMID: 21482989    Free PMC article.
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Eva J Kantelhardt, Martina Vetter, +12 authors, Nadia Harbeck.
BMC Cancer, 2011 Apr 19; 11. PMID: 21496284    Free PMC article.
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.
Hao Liu, Christina Tekle, +10 authors, Ming Tan.
Mol Cancer Ther, 2011 Apr 27; 10(6). PMID: 21518725    Free PMC article.
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
David L Rimm, Torsten O Nielsen, +18 authors, Cancer and Leukemia Group B Pathology Committee.
J Clin Oncol, 2011 Apr 27; 29(16). PMID: 21519016    Free PMC article.
Regulation of mitosis and taxane response by Daxx and Rassf1.
S Giovinazzi, C R Lindsay, +5 authors, A M Ishov.
Oncogene, 2011 Jun 07; 31(1). PMID: 21643015    Free PMC article.
The International Core Literature Consensus (ICLC): an alternative curriculum for Oncologists.
Shilpen Patel, Reshma Jagsi, +2 authors, Christine Parkinson.
J Cancer Educ, 2011 Jun 07; 26(3). PMID: 21644006
p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).
Jonathan F Lara, Ann D Thor, +15 authors, Cancer and Leukemia Group B.
Clin Cancer Res, 2011 Jun 23; 17(15). PMID: 21693655    Free PMC article.
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221).
Lara E Sucheston, Hua Zhao, +18 authors, Christine B Ambrosone.
Breast Cancer Res Treat, 2011 Jul 19; 130(3). PMID: 21766209    Free PMC article.
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
Donald A Berry, Naoto T Ueno, +21 authors, Taner Demirer.
J Clin Oncol, 2011 Jul 20; 29(24). PMID: 21768471    Free PMC article.
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials.
Jordi Ginés, Eliazar Sabater, +3 authors, Miguel A Casado.
Clin Transl Oncol, 2011 Jul 22; 13(7). PMID: 21775276
Review.
18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.
Shigeto Ueda, Toshiaki Saeki, +15 authors, Hiroshi Matsuda.
Int J Clin Oncol, 2011 Aug 11; 17(3). PMID: 21830087
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
P Vici, M Brandi, +11 authors, M Lopez.
Ann Oncol, 2011 Oct 04; 23(5). PMID: 21965475    Free PMC article.
Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials.
James E Herndon, Alice B Kornblith, Jimmie C Holland, Electra D Paskett.
Psychooncology, 2011 Oct 25; 22(2). PMID: 22021121    Free PMC article.
Clinical trials in the era of personalized oncology.
Michael L Maitland, Richard L Schilsky.
CA Cancer J Clin, 2011 Oct 29; 61(6). PMID: 22034206    Free PMC article.
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
Banu K Arun, Kapil Dhinghra, +16 authors, Gabriel N Hortobagyi.
Oncologist, 2011 Nov 02; 16(11). PMID: 22042783    Free PMC article.
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Jocelyne Jacquemier, Jean-Marie Boher, +12 authors, François Bertucci.
Breast Cancer Res, 2011 Nov 03; 13(6). PMID: 22044691    Free PMC article.
Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients.
Ying-Yi Qin, Hui Li, +8 authors, Jia He.
PLoS One, 2011 Nov 10; 6(11). PMID: 22069477    Free PMC article.
Systematic Review.
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.
Yuko Tanabe, Kenji Hashimoto, +9 authors, Yasuhiro Fujiwara.
Int J Clin Oncol, 2011 Nov 23; 18(1). PMID: 22105895
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Larisa Sheihet, Olga B Garbuzenko, +3 authors, Joachim Kohn.
Eur J Pharm Sci, 2011 Dec 14; 45(3). PMID: 22155544    Free PMC article.
Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers.
A V Tinker, C Speers, +2 authors, S Chia.
Ecancermedicalscience, 2008 Jan 01; 2. PMID: 22275960    Free PMC article.
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Harry D Bear, Gong Tang, +17 authors, Norman Wolmark.
N Engl J Med, 2012 Jan 27; 366(4). PMID: 22276821    Free PMC article.
Highly Cited.
Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.
A VanderWalde, W Ye, +14 authors, G Somlo.
Biol Blood Marrow Transplant, 2012 Feb 07; 18(8). PMID: 22306735    Free PMC article.
Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis.
Bohuslav Melichar, Helena Hornychová, +7 authors, Aleš Ryška.
Med Oncol, 2012 Mar 07; 29(4). PMID: 22392196
Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).
Ayesha N Shajahan, Zachary C Dobbin, +2 authors, Robert Clarke.
J Biol Chem, 2012 Mar 22; 287(21). PMID: 22433870    Free PMC article.
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.
Uchenna O Njiaju, Eric R Gamazon, +4 authors, M Eileen Dolan.
Pharmacogenet Genomics, 2012 Mar 23; 22(7). PMID: 22437668    Free PMC article.
Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.
Hajime Abe, Tsuyoshi Mori, +5 authors, Tohru Tani.
Int J Clin Oncol, 2012 Apr 10; 18(3). PMID: 22484576
High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.
Dongliang Zhu, Xiaoming Zha, +4 authors, Yujie Sun.
Med Oncol, 2012 May 01; 29(5). PMID: 22544540
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Lynnette Fernández-Cuesta, Catherine Oakman, +14 authors, Magali Olivier.
Breast Cancer Res, 2012 May 04; 14(3). PMID: 22551440    Free PMC article.
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.
Per E Lønning.
Ther Adv Med Oncol, 2012 May 17; 4(3). PMID: 22590486    Free PMC article.
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Bruno Coudert, Bernard Asselain, +18 authors, UNICANCER Breast Group.
Oncologist, 2012 May 23; 17(7). PMID: 22610153    Free PMC article.
Decline in the use of anthracyclines for breast cancer.
Sharon H Giordano, Yu-Li Lin, +2 authors, James S Goodwin.
J Clin Oncol, 2012 May 23; 30(18). PMID: 22614988    Free PMC article.
Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs.
Yong Tsuey Li, Ming Jang Chua, Anil Philip Kunnath, Ezharul Hoque Chowdhury.
Int J Nanomedicine, 2012 Jun 16; 7. PMID: 22701315    Free PMC article.
Recent advances in adjuvant systemic treatment for breast cancer: all systems go!
P N Fishman, S Verma.
Curr Oncol, 2006 Oct 01; 13(5). PMID: 22792012    Free PMC article.
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Lawrence N Shulman, Constance T Cirrincione, +12 authors, Clifford Hudis.
J Clin Oncol, 2012 Jul 25; 30(33). PMID: 22826271    Free PMC article.
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
Bryan P Schneider, Fengmin Zhao, +10 authors, Joseph A Sparano.
J Clin Oncol, 2012 Aug 02; 30(25). PMID: 22851566    Free PMC article.
Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel.
Isabel R Schlaepfer, Carolyn A Hitz, +3 authors, Britta M Jacobsen.
Mol Cell Endocrinol, 2012 Aug 28; 363(1-2). PMID: 22922095    Free PMC article.
Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.
Kun Wang, Quan-Tong Deng, +6 authors, Yi-Long Wu.
Tumour Biol, 2012 Sep 15; 34(1). PMID: 22976542
Publication of tumor marker research results: the necessity for complete and transparent reporting.
Lisa M McShane, Daniel F Hayes.
J Clin Oncol, 2012 Oct 17; 30(34). PMID: 23071235    Free PMC article.
Review.
Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.
Allison W Kurian, Daphne Y Lichtensztajn, +8 authors, Scarlett L Gomez.
Breast Cancer Res Treat, 2012 Nov 10; 137(1). PMID: 23139057    Free PMC article.
Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.
Hidemi Kawajiri, Tsutomu Takashima, +5 authors, Kosei Hirakawa.
Oncol Lett, 2012 Dec 04; 4(4). PMID: 23205071    Free PMC article.
Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort.
Carrie A Geisberg, Wissam M Abdallah, +9 authors, Douglas B Sawyer.
J Card Fail, 2013 Jan 01; 19(1). PMID: 23273589    Free PMC article.
Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
H Sakr, R H Hamed, A H Anter, T Yossef.
Med Oncol, 2013 Jan 17; 30(1). PMID: 23322524
Future vision for the quality assurance of oncology clinical trials.
Thomas J Fitzgerald, Maryann Bishop-Jodoin, +15 authors, Marcia Urie.
Front Oncol, 2013 Mar 20; 3. PMID: 23508883    Free PMC article.
BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.
M Sung, P Giannakakou.
Oncogene, 2013 Mar 26; 33(11). PMID: 23524581    Free PMC article.
Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia.
A E Lohmann, C H Speers, S K Chia.
Curr Oncol, 2013 Apr 06; 20(2). PMID: 23559872    Free PMC article.
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
Chiaojung Jillian Tsai, Jing Li, +10 authors, Thomas A Buchholz.
Am J Clin Oncol, 2013 May 08; 38(3). PMID: 23648437    Free PMC article.
Overview of major classes of plant-derived anticancer drugs.
Amr Amin, Hala Gali-Muhtasib, Matthias Ocker, Regine Schneider-Stock.
Int J Biomed Sci, 2009 Mar 01; 5(1). PMID: 23675107    Free PMC article.
Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis.
Ke-Da Yu, Sheng Huang, +2 authors, Zhi-Ming Shao.
BMC Cancer, 2013 May 18; 13. PMID: 23679207    Free PMC article.
Systematic Review.
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
Dawn L Hershman, Joseph M Unger, +12 authors, Kathy S Albain.
J Clin Oncol, 2013 Jun 05; 31(20). PMID: 23733756    Free PMC article.
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.
G H Lyman, D C Dale, +5 authors, J Crawford.
Ann Oncol, 2013 Jun 22; 24(10). PMID: 23788754    Free PMC article.
Systematic Review.
Hormonal therapies in young breast cancer patients: when, what and for how long?
Alexandre Christinat, Simona Di Lascio, Olivia Pagani.
J Thorac Dis, 2013 Jul 03; 5 Suppl 1. PMID: 23819026    Free PMC article.
Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study.
Sho Hangai, Satoru Iwase, +5 authors, Takuhiro Yamaguchi.
J Altern Complement Med, 2013 Jul 09; 19(11). PMID: 23829813    Free PMC article.
Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer.
Alexandra Schönherr, Viktoria Aivazova-Fuchs, +14 authors, Brigitte Rack.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904831    Free PMC article.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark.
J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225    Free PMC article.
Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens.
Yasser Abdel Kader, Tamer El-Nahas, Amr Sakr.
Onco Targets Ther, 2013 Aug 24; 6. PMID: 23966793    Free PMC article.
Effect of chemotherapy for luminal a breast cancer.
Naotaka Uchida, Takako Suda, Kiyosuke Ishiguro.
Yonago Acta Med, 2013 Sep 14; 56(2). PMID: 24031152    Free PMC article.
Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.
Mark E Burkard, Kari B Wisinski, +11 authors, Amye J Tevaarwerk.
Clin Breast Cancer, 2013 Dec 18; 14(3). PMID: 24342730    Free PMC article.
Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer.
W Si, Y Y Zhu, +6 authors, J L Yang.
Braz J Med Biol Res, 2013 Dec 19; 46(12). PMID: 24345917    Free PMC article.
Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling.
Pei Dong, Lijuan Jiang, +5 authors, Zhuowei Liu.
PLoS One, 2014 Jan 01; 8(12). PMID: 24376711    Free PMC article.
Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.
Isabella Sperduti, Patrizia Vici, +6 authors, Clara Natoli.
J Exp Clin Cancer Res, 2014 Jan 21; 32. PMID: 24438135    Free PMC article.
Systematic Review.
Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institution.
S Corradini, O M Niemoeller, +5 authors, S Kahlert.
Strahlenther Onkol, 2014 Mar 19; 190(4). PMID: 24638237
Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
Katsunori Tozuka, Jun Horiguchi, +7 authors, Izumi Takeyoshi.
Mol Clin Oncol, 2013 Jan 01; 1(1). PMID: 24649129    Free PMC article.
Survival of women with inflammatory breast cancer: a large population-based study.
S Dawood, X Lei, +6 authors, A M Gonzalez-Angulo.
Ann Oncol, 2014 Mar 29; 25(6). PMID: 24669011    Free PMC article.
Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Daniel L Hertz, Siddharth Roy, +6 authors, Howard L McLeod.
Breast Cancer Res Treat, 2014 Apr 08; 145(1). PMID: 24706167    Free PMC article.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Miguel Martin, Jan C Brase, +15 authors, Alvaro Rodriguez-Lescure.
Breast Cancer Res, 2014 Apr 15; 16(2). PMID: 24725534    Free PMC article.
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.
R Kreienberg, U-S Albert, +3 authors, A Wöckel.
Geburtshilfe Frauenheilkd, 2014 Apr 29; 73(6). PMID: 24771925    Free PMC article.
Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Rachel Webber-Foster, Giorgi Kvizhinadze, Gareth Rivalland, Tony Blakely.
Pharmacoeconomics, 2014 May 27; 32(7). PMID: 24859241
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.
Sara A Hurvitz, Linda D Bosserman, +6 authors, Dennis J Slamon.
Springerplus, 2014 May 27; 3. PMID: 24860718    Free PMC article.
Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer.
Xia Liu, Yong Guan, +5 authors, Yun Niu.
Tumour Biol, 2014 May 28; 35(9). PMID: 24863944
Past, present, and future challenges in breast cancer treatment.
George W Sledge, Eleftherios P Mamounas, +3 authors, Antonio C Wolff.
J Clin Oncol, 2014 Jun 04; 32(19). PMID: 24888802    Free PMC article.
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Lawrence N Shulman, Donald A Berry, +12 authors, Eric P Winer.
J Clin Oncol, 2014 Jun 18; 32(22). PMID: 24934787    Free PMC article.
The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatment.
Norahayu Othman, Noor Hasima Nagoor.
Biomed Res Int, 2014 Jul 08; 2014. PMID: 24999473    Free PMC article.
Review.
Gingerol-derivatives: emerging new therapy against human drug-resistant MCF-7.
Ahmed S Ibrahim, Mohamed A M Sobh, +7 authors, Farid A Badria.
Tumour Biol, 2014 Jul 10; 35(10). PMID: 25004806
Pathogenesis, prevention, diagnosis and treatment of breast cancer.
Rupen Shah, Kelly Rosso, S David Nathanson.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114845    Free PMC article.
Review.
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
J Salvador, L Manso, +13 authors, P Sanchez Rvira.
Clin Transl Oncol, 2014 Aug 15; 17(2). PMID: 25119930
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
Very late relapse in breast cancer survivors: a report of 6 cases.
Shapour Omidvari, Seyed Hasan Hamedi, +5 authors, Mansour Ansari.
Iran J Cancer Prev, 2013 Apr 01; 6(2). PMID: 25250120    Free PMC article.
Comparison of cantharidin toxicity in breast cancer cells to two common chemotherapeutics.
Katie M Kern, Jennifer R Schroeder.
Int J Breast Cancer, 2014 Oct 11; 2014. PMID: 25302124    Free PMC article.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.
Elizabeth Miller, Hee Jin Lee, +3 authors, Bora Lim.
F1000Res, 2014 Nov 18; 3. PMID: 25400908    Free PMC article.
Review.
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Antonio C Wolff, Amanda L Blackford, +10 authors, Judith E Karp.
J Clin Oncol, 2014 Dec 24; 33(4). PMID: 25534386    Free PMC article.
Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.
Jie Zhou, Shikun Qian, +6 authors, Rongcheng Luo.
Tumour Biol, 2015 Mar 17; 36(5). PMID: 25773385
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Review.
Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007.
Henry G Kaplan, Judith A Malmgren, Mary K Atwood, Gregory S Calip.
Cancer, 2015 Apr 16; 121(15). PMID: 25872471    Free PMC article.
Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Meyha N Swaroop, Chantal M Ferguson, +8 authors, Alphonse G Taghian.
Breast Cancer Res Treat, 2015 May 06; 151(2). PMID: 25940996    Free PMC article.
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
Angelos Koutras, Konstantine T Kalogeras, +16 authors, George Fountzilas.
J Transl Med, 2015 May 30; 13. PMID: 26021752    Free PMC article.
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials.
Rodrigo Fresco, Gonzalo Spera, +2 authors, John R Mackey.
Oncologist, 2015 May 31; 20(7). PMID: 26025934    Free PMC article.
Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane.
Hyeon Kang Koh, Kyung Hwan Shin, +14 authors, Sung Whan Ha.
Cancer Res Treat, 2015 Jun 06; 48(2). PMID: 26044160    Free PMC article.
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Joseph A Sparano, Fengmin Zhao, +7 authors, Nancy E Davidson.
J Clin Oncol, 2015 Jun 17; 33(21). PMID: 26077235    Free PMC article.
β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer.
Youqun Xiang, Yinlong Yang, +4 authors, Yifei Pan.
Clin Exp Med, 2015 Jun 20; 16(3). PMID: 26088183
Treatment Outcome of Breast Cancer with Pathologically Proven Synchronous Ipsilateral Supraclavicular Lymph Node Metastases.
Jinhong Jung, Su Ssan Kim, +5 authors, Eun Kyung Choi.
J Breast Cancer, 2015 Jul 15; 18(2). PMID: 26155293    Free PMC article.
Current approaches in treatment of triple-negative breast cancer.
Hanan Ahmed Wahba, Hend Ahmed El-Hadaad.
Cancer Biol Med, 2015 Jul 16; 12(2). PMID: 26175926    Free PMC article.
Highly Cited. Review.
Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population.
Lea Rossi, Denise Stevens, +5 authors, Roman Rouzier.
PLoS One, 2015 Jul 28; 10(7). PMID: 26214853    Free PMC article.
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Harry D Bear, Gong Tang, +18 authors, Norman Wolmark.
Lancet Oncol, 2015 Aug 15; 16(9). PMID: 26272770    Free PMC article.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
Jee Suk Chang, Jeongshim Lee, +7 authors, Yong Bae Kim.
Medicine (Baltimore), 2015 Aug 20; 94(33). PMID: 26287410    Free PMC article.
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Neil M Iyengar, Monica N Fornier, +17 authors, Chau T Dang.
Clin Breast Cancer, 2015 Oct 12; 16(2). PMID: 26454612    Free PMC article.
Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.
S Rahal, J M Boher, +12 authors, A Gonçalves.
BMC Cancer, 2015 Oct 16; 15. PMID: 26466893    Free PMC article.
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Yuka Asano, Shinichiro Kashiwagi, +6 authors, Kosei Hirakawa.
Ann Surg Oncol, 2015 Oct 30; 23(4). PMID: 26511266    Free PMC article.
Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients.
J Giuliani, A Mercanti, A Bonetti.
Clin Transl Oncol, 2015 Nov 01; 18(8). PMID: 26519364
Mammography screening in less developed countries.
JunJie Li, ZhiMin Shao.
Springerplus, 2015 Nov 07; 4. PMID: 26543750    Free PMC article.
Review.
Breast Cancer: State of the Art and New Findings.
C Melcher, C Scholz, +3 authors, W Janni.
Geburtshilfe Frauenheilkd, 2012 Mar 01; 72(3). PMID: 26640286    Free PMC article.
Chemotherapy in Premenopausal Breast Cancer Patients.
Ann H Partridge.
Breast Care (Basel), 2015 Dec 22; 10(5). PMID: 26688676    Free PMC article.
Review.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
Jean E Abraham, Louise Hiller, +11 authors, Helena M Earl.
BMC Med, 2015 Dec 31; 13. PMID: 26715442    Free PMC article.
Efficacy of chemotherapy after hormone therapy for hormone receptor-positive metastatic breast cancer.
Ryutaro Mori, Yasuko Nagao.
SAGE Open Med, 2014 Jan 01; 2. PMID: 26770749    Free PMC article.
Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer.
Heather Greenlee, Katherine D Crew, +9 authors, Dawn L Hershman.
Breast Cancer Res Treat, 2016 Mar 26; 156(3). PMID: 27013473    Free PMC article.
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
W Janni, N Harbeck, +9 authors, M Kiechle.
Br J Cancer, 2016 Apr 01; 114(8). PMID: 27031854    Free PMC article.
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Xue-Lian Chen, Feng Du, +5 authors, Bing-He Xu.
Chin J Cancer, 2016 Apr 27; 35. PMID: 27112139    Free PMC article.
Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era: A Retrospective Korean Breast Cancer Society Report.
Jee Suk Chang, Jung Eun Choi, +6 authors, Korean Breast Cancer Society.
Medicine (Baltimore), 2016 May 14; 95(19). PMID: 27175662    Free PMC article.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy.
JunJie Li, Sheng Chen, +4 authors, ZhiMin Shao.
Oncotarget, 2016 May 19; 8(11). PMID: 27191991    Free PMC article.
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
L Schröder, B Rack, +13 authors, C Scholz.
Geburtshilfe Frauenheilkd, 2016 May 31; 76(5). PMID: 27239063    Free PMC article.
Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.
Rachna Raman, Sarah L Mott, +3 authors, Alexandra Thomas.
Clin Breast Cancer, 2016 Jul 20; 16(6). PMID: 27431461    Free PMC article.
Platelet-Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer.
Yuka Asano, Shinichiro Kashiwagi, +6 authors, Kosei Hirakawa.
PLoS One, 2016 Jul 30; 11(7). PMID: 27472762    Free PMC article.
A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes.
Junmei Cairns, Choong Yong Ung, +5 authors, Hu Li.
Sci Rep, 2016 Nov 15; 6. PMID: 27841317    Free PMC article.
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.
Rachel A Freedman, Jared C Foster, +13 authors, Arti Hurria.
J Clin Oncol, 2016 Dec 20; 35(4). PMID: 27992272    Free PMC article.
A Multi-Mitochondrial Anticancer Agent that Selectively Kills Cancer Cells and Overcomes Drug Resistance.
Yong Bo Peng, Zi Long Zhao, +9 authors, Wei Hong Tan.
ChemMedChem, 2017 Jan 18; 12(3). PMID: 28098432    Free PMC article.
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Joanne L Blum, Patrick J Flynn, +19 authors, Norman Wolmark.
J Clin Oncol, 2017 Apr 12; 35(23). PMID: 28398846    Free PMC article.
Highly Cited.
Opening the LOX to bone metastasis: The role of secreted lysyl oxidase in skeletal recurrence of breast cancers.
Maryam K Mohammed, Connie Shao, Hue H Luu, Rex C Haydon.
Genes Dis, 2015 Dec 01; 2(4). PMID: 28529966    Free PMC article.
Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.
Ravi K Goyal, Spiros Tzivelekis, +2 authors, James A Kaye.
Support Care Cancer, 2017 Sep 19; 26(2). PMID: 28921379
A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.
Qiao Li, Zhao Yang, +8 authors, Pin Zhang.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100275    Free PMC article.
21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Eleftherios P Mamounas, Gong Tang, +14 authors, Norman Wolmark.
Breast Cancer Res Treat, 2017 Nov 13; 168(1). PMID: 29128898    Free PMC article.
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Alexios Matikas, Sara Margolin, +12 authors, Jonas Bergh.
Breast Cancer Res Treat, 2017 Dec 01; 168(2). PMID: 29190004    Free PMC article.
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
Steffen Dörfel, Claus-Christoph Steffens, +6 authors, TMK-Group (Tumour Registry Breast Cancer).
Breast Cancer, 2017 Dec 06; 25(3). PMID: 29204847    Free PMC article.
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Lara E Sucheston-Campbell, Alyssa I Clay-Gilmour, +23 authors, Christine B Ambrosone.
Pharmacogenet Genomics, 2017 Dec 27; 28(2). PMID: 29278617    Free PMC article.
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
Yuka Asano, Shinichiro Kashiwagi, +11 authors, Masaichi Ohira.
BMC Cancer, 2017 Dec 29; 17(1). PMID: 29282021    Free PMC article.
Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario.
Kristi Orbaugh, Joanne C Ryan, Lynn Pfeuffer.
J Adv Pract Oncol, 2016 Jul 01; 7(5). PMID: 29282430    Free PMC article.
Review.
Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.
Emi Ishigami, Masahiro Sakakibara, +8 authors, Masayuki Otsuka.
Mol Clin Oncol, 2017 Dec 30; 7(6). PMID: 29285378    Free PMC article.
Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis.
Qiao-Hui Zhan, Jian-Qin Fu, +2 authors, Chuan Wang.
Oncotarget, 2018 Feb 09; 9(2). PMID: 29416807    Free PMC article.
Recent Improvement in the Long-term Survival of Breast Cancer Patients by Age and Stage in Japan.
Akiyo Yoshimura, Hidemi Ito, +8 authors, Yuri Ito.
J Epidemiol, 2018 Feb 27; 28(10). PMID: 29479003    Free PMC article.
Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study.
Sae Byul Lee, Guiyun Sohn, +7 authors, Sei-Hyun Ahn.
J Breast Cancer, 2018 Apr 10; 21(1). PMID: 29628986    Free PMC article.
Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Karen A Cadoo, Peter A Kaufman, +3 authors, Tiffany A Traina.
Clin Breast Cancer, 2018 Jun 14; 18(6). PMID: 29895438    Free PMC article.
Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
M Martín, J C de la Torre-Montero, +13 authors, A Lluch.
Breast Cancer Res Treat, 2018 Jun 21; 171(3). PMID: 29923063    Free PMC article.
Mechanical Alteration Associated With Chemotherapeutic Resistance of Breast Cancer Cells.
Soyeun Park.
J Cancer Prev, 2018 Jul 14; 23(2). PMID: 30003069    Free PMC article.
The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine.
Javad Javan-Noughabi, Aziz Rezapour, +2 authors, Niloofar Ahmadloo.
J Res Med Sci, 2018 Jul 31; 23. PMID: 30057641    Free PMC article.
Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Ami N Shah, William J Gradishar.
Oncologist, 2018 Aug 19; 23(10). PMID: 30120159    Free PMC article.
Review.
A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer.
Nuri Karadurmus, Ugur Sahin, +2 authors, Taner Demirer.
Int J Hematol Oncol Stem Cell Res, 2018 Sep 21; 12(2). PMID: 30233772    Free PMC article.
Review.
Impact of Delayed Adjuvant Radiotherapy in the Survival of Women with Breast Cancer.
Christian H Flores-Balcázar, Lourdes Flores-Luna, +2 authors, Enrique Bargalló-Rocha.
Cureus, 2018 Dec 05; 10(7). PMID: 30510860    Free PMC article.
Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
W Iris Zhi, Patricia Chen, +7 authors, Ting Bao.
Breast Cancer Res Treat, 2019 Aug 29; 178(3). PMID: 31456070    Free PMC article.
Taxanes for adjuvant treatment of early breast cancer.
Melina L Willson, Lucinda Burke, +3 authors, Nicholas Wilcken.
Cochrane Database Syst Rev, 2019 Sep 03; 9. PMID: 31476253    Free PMC article.
Systematic Review.
Improving chemotherapy outcome in early breast cancer.
Anurag Gupta, Rohit Joshi.
Gland Surg, 2019 Nov 20; 8(5). PMID: 31741891    Free PMC article.
Level III dissection in locally advanced breast cancer following neoadjuvant chemotherapy: a retrospective study.
R V Bhargavan, A Mirza, +2 authors, P Augustine.
Ann R Coll Surg Engl, 2019 Nov 23; 102(3). PMID: 31755729    Free PMC article.
The use of a predictive statistical model to make a virtual control arm for a clinical trial.
Jeffrey M Switchenko, Arielle L Heeke, Tony C Pan, William L Read.
PLoS One, 2019 Sep 05; 14(9). PMID: 31483824    Free PMC article.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2019 Feb 12; 393(10179). PMID: 30739743    Free PMC article.
Highly Cited.
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
Hiroyuki Nomura, Daisuke Aoki, +15 authors, Japanese Gynecologic Oncology Group.
JAMA Oncol, 2019 Mar 22; 5(6). PMID: 30896757    Free PMC article.
Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).
Dyda Dao, Tyler Zemla, +13 authors, Jennifer G Le-Rademacher.
Oncologist, 2019 Apr 13; 24(6). PMID: 30975921    Free PMC article.
Gamma Tocopherol Reduced Chemotherapeutic-Induced ROS in an Ovarian Granulosa Cell Line, But Not in Breast Cancer Cell Lines In Vitro.
Daniela Figueroa Gonzalez, Fiona Young.
Antioxidants (Basel), 2020 Jan 16; 9(1). PMID: 31936058    Free PMC article.
Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study.
Diriba Alemayehu Gadisa, Mathewos Assefa, Gosaye Mekonen Tefera, Getnet Yimer.
J Oncol, 2020 Mar 10; 2020. PMID: 32148494    Free PMC article.
Assessing the Effects of Redox Modifier MnTnBuOE-2-PyP 5+ on Cognition and Hippocampal Physiology Following Doxorubicin, Cyclophosphamide, and Paclitaxel Treatment.
Taylor McElroy, Taurean Brown, +4 authors, Antiño R Allen.
Int J Mol Sci, 2020 Mar 19; 21(5). PMID: 32182883    Free PMC article.
The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.
Erina Hilaj, Alketa Ymeri, Kleva P Shpati.
Cureus, 2020 Apr 08; 12(2). PMID: 32257663    Free PMC article.
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Mauricio A Medina, Goldie Oza, +4 authors, Jose Tapia Ramirez.
Int J Environ Res Public Health, 2020 Apr 05; 17(6). PMID: 32245065    Free PMC article.
Review.
Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
Elvira C van Dalen, Helena J H van der Pal, Leontien C M Kremer.
Cochrane Database Syst Rev, 2016 Mar 05; 3. PMID: 26938118    Free PMC article.
Systematic Review.
Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
Anna Diana, Francesca Carlino, +5 authors, Michele Orditura.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235297    Free PMC article.
Review.
PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression.
Teresa Gagliano, Kalpit Shah, +24 authors, Georgios Giamas.
J Clin Invest, 2020 Mar 04; 130(6). PMID: 32125284    Free PMC article.
Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer.
Ashok K Vaid, Aseem Khurana, +6 authors, Kush Gupta.
World J Oncol, 2020 Jun 05; 11(3). PMID: 32494317    Free PMC article.
A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019.
Taylor McElroy, Antiño R Allen.
Antioxidants (Basel), 2020 May 24; 9(5). PMID: 32443630    Free PMC article.
Review.
Triple-negative breast cancer molecular subtyping and treatment progress.
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian, Shi-Cang Yu.
Breast Cancer Res, 2020 Jun 11; 22(1). PMID: 32517735    Free PMC article.
Review.
Coronary Event Analysis in Breast Cancer Patients Who Received Breast-Conserving Surgery and Post-Operative Radiotherapy: a Korean Nationwide Cohort Study.
Soo-Yoon Sung, Jong Hoon Lee, +2 authors, Mi Yeon Kang.
J Breast Cancer, 2020 Jul 01; 23(3). PMID: 32595991    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
Review.
The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients.
Wanwan Qi, Xiaoyi Wang, +3 authors, Qiao Cheng.
Sci Rep, 2020 Aug 09; 10(1). PMID: 32764734    Free PMC article.
New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer.
Sherry X Yang, Eric Polley, Stanley Lipkowitz.
Cancer Treat Rev, 2016 Mar 21; 45. PMID: 26995633    Free PMC article.
Highly Cited. Review.
Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling.
Dan Georgess, Veena Padmanaban, +6 authors, Andrew J Ewald.
Cancer Res, 2019 Nov 05; 80(2). PMID: 31676574    Free PMC article.
Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: A cross-sectional study.
Jinfei Ma, Emmanuel Eric Pazo, Zihao Zou, Feng Jin.
Breast, 2020 Aug 25; 53. PMID: 32836200    Free PMC article.
Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study.
Hikmat N Abdel-Razeq, Razan A Mansour, +4 authors, Omar A Shahin.
Medicine (Baltimore), 2020 Mar 17; 99(11). PMID: 32176115    Free PMC article.
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study.
Atul Batra, Malek B Hannouf, Noura Alsafar, Sasha Lupichuk.
Breast, 2020 Aug 31; 54. PMID: 32861882    Free PMC article.
Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy.
Xuran Zhao, Yu Tang, +17 authors, Yexiong Li.
Radiat Oncol, 2020 Sep 06; 15(1). PMID: 32887640    Free PMC article.
Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates.
Fernando Kude de Almeida, Daniela Dornelles Rosa.
Breast Care (Basel), 2019 Feb 26; 13(6). PMID: 30800040    Free PMC article.
Review.
Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study.
Jaeho Kim, Won Park, +13 authors, Jihye Cha.
Cancers (Basel), 2019 May 19; 11(5). PMID: 31100839    Free PMC article.
Pure Mucinous Breast Carcinoma with Micropapillary Pattern (MUMPC): A Case Report.
Yuka Asano, Shinichiro Kashiwagi, +7 authors, Masaichi Ohira.
Case Rep Oncol, 2019 Aug 21; 12(2). PMID: 31427951    Free PMC article.
Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial.
Daniela Koppold-Liebscher, Christian S Kessler, +11 authors, Andreas Michalsen.
Trials, 2020 Oct 17; 21(1). PMID: 33059765    Free PMC article.
The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis.
Sanxing Guo, Yonggang Shi, +4 authors, Xingya Li.
J Cancer, 2020 Oct 14; 11(22). PMID: 33046986    Free PMC article.
Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
Hye Sung Won, Yong Seok Kim, +4 authors, Dong Soo Lee.
Korean J Intern Med, 2020 Feb 20; 35(6). PMID: 32069523    Free PMC article.
Do all patients with breast cancer benefit from neoadjuvant chemotherapy?
Kyoung Eun Lee.
Korean J Intern Med, 2020 Nov 06; 35(6). PMID: 33147906    Free PMC article.
Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Toru Watanabe, Masaru Kuranami, +7 authors, Yasuo Ohashi.
Cancer, 2017 Jan 13; 123(5). PMID: 28081304    Free PMC article.
Adjuvant continuous metronomic adriamycin + cyclophosphamide followed by weekly nab-paclitaxel for high-risk early-stage breast cancer.
Eunpi Cho, Qian Wu, +5 authors, Georgiana Ellis.
Breast J, 2018 Mar 14; 24(4). PMID: 29532546    Free PMC article.
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
Achim Wöckel, Jasmin Festl, +94 authors, Stephanie Stangl.
Geburtshilfe Frauenheilkd, 2018 Dec 26; 78(11). PMID: 30581198    Free PMC article.
Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology.
Panagiotis Ntellas, Nikolaos Spathas, +2 authors, Emmanouil Saloustros.
Oncotarget, 2019 Mar 07; 10(11). PMID: 30838092    Free PMC article.
Taxane-based chemotherapy and risk of breast cancer-related lymphedema: Protocol for a systematic review and meta-analysis.
Zhenhua Zhang, Xiwen Zhang, +7 authors, Baojin Hua.
Medicine (Baltimore), 2019 Jul 28; 98(30). PMID: 31348280    Free PMC article.
Nano-Co-Delivery of Berberine and Anticancer Drug Using PLGA Nanoparticles: Exploration of Better Anticancer Activity and In Vivo Kinetics.
Iliyas Khan, Gaurav Joshi, +3 authors, Umesh Gupta.
Pharm Res, 2019 Aug 20; 36(10). PMID: 31420752
Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: study protocol of the i-GO study.
Josanne S de Maar, Britt B M Suelmann, +7 authors, Roel Deckers.
BMJ Open, 2020 Nov 28; 10(11). PMID: 33243800    Free PMC article.
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Riccardo Lobefaro, Emma Zattarin, +15 authors, Giuseppe Capri.
Ther Adv Med Oncol, 2020 Dec 19; 12. PMID: 33335565    Free PMC article.
Virtual controls as an alternative to randomized controlled trials for assessing efficacy of interventions.
Joseph M Strayhorn.
BMC Med Res Methodol, 2021 Jan 07; 21(1). PMID: 33402097    Free PMC article.
Review.
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Dena Firouzabadi, Amirreza Dehghanian, +2 authors, Abdolrasoul Talei.
BMC Cancer, 2021 Jan 13; 21(1). PMID: 33430808    Free PMC article.
KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
Mei Zhou, Prabhakar Pitta Venkata, +13 authors, Gangadhara R Sareddy.
Breast Cancer Res Treat, 2020 Oct 16; 185(2). PMID: 33057995
Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer.
Wanjing Chen, Qian Tu, +3 authors, Yong Shen.
World J Surg Oncol, 2021 Feb 20; 19(1). PMID: 33602236    Free PMC article.
Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
Gwen M H E Dackus, Katarzyna Jóźwiak, +5 authors, Sabine C Linn.
Breast Cancer Res Treat, 2020 Oct 29; 185(3). PMID: 33113088    Free PMC article.
Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.
Qiaoping Xu, Li Yuanyuan, +7 authors, Yan Wei.
Cost Eff Resour Alloc, 2021 Feb 25; 19(1). PMID: 33622356    Free PMC article.
Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System.
Taurean Brown, DeLawrence Sykes, Antiño R Allen.
Biomedicines, 2021 Mar 07; 9(2). PMID: 33668580    Free PMC article.
Review.
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
Miguel Martin, Rocio Ramos-Medina, +20 authors, Sara Lopez-Tarruella.
Sci Rep, 2021 Mar 31; 11(1). PMID: 33782404    Free PMC article.